A - Agilent Technologies
134.51
| Index: | S&P 500 | P/E: | 30.38 | EPS (ttm): | 4.43 | Insider Own: | 0.43% | Shs Outstand: | 287.33M | Perf Week: | -3.23% |
| Market Cap: | 39.03B | Forward P/E: | 22.02 | EPS next Y: | 6.11 | Insider Trans: | -1.50% | Shs Float: | 286.10M | Perf Month: | 4.62% |
| Income(ttm): | 1.29B | PEG: | 3.80 | EPS next Q: | 1.27 | Inst Own: | 90.55% | Short Float: | 1.00% | Perf Quarter: | -3.78% |
| Revenue(ttm): | 6.51B | P/S: | 6.00 | EPS this Y: | 5.15% | Inst Trans: | -1.24% | Short Ratio: | 1.62 | Perf Half Y: | -0.42% |
| Book/sh: | 20.68 | P/B: | 6.50 | EPS next Y: | 9.79% | ROA: | 11.36% | Short Interest: | 2.87M | Perf Year: | -2.66% |
| Cash/sh: | 4.58 | P/C: | 29.37 | EPS next 5Y: | 8.00% | ROE: | 21.95% | 52W Range: | 124.16 - 155.35 | Perf YTD: | -3.25% |
| Dividend Est.: | 1.00 (0.74%) | P/FCF: | 28.43 | EPS past 5Y: | 5.63% | ROI: | 13.73% | 52W High: | -13.41% | Beta: | 1.07 |
| Dividend TTM: | 0.94 (0.70%) | Quick Ratio: | 1.58 | Sales past 5Y: | 5.04% | Gross Margin: | 54.72% | 52W Low: | 8.34% | ATR (14): | 3.32 |
| Dividend Ex-Date: | Dec 31, 2024 | Current Ratio: | 2.09 | EPS Y/Y TTM: | 5.34% | Oper. Margin: | 24.52% | RSI (14): | 44.65 | Volatility: | 2.34% 2.47% |
| Employees: | 17900 | Debt/Eq: | 0.61 | Sales Y/Y TTM: | -4.73% | Profit Margin: | 19.80% | Recom: | 2.33 | Target Price: | 149.07 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.59 | EPS Q/Q: | -24.56% | Payout: | 21.31% | Rel Volume: | 2.46 | Prev Close: | 133.19 |
| Sales Surprise: | 1.10% | EPS Surprise: | 3.54% | Sales Q/Q: | 0.77% | Earnings: | Nov 25 AMC | Avg Volume: | 1.76M | Price: | 134.51 |
| SMA20: | -2.47% | SMA50: | -1.07% | SMA200: | -3.00% | Undervalued: 10.82% | Volume: | 4,342,841 | Change: | 0.99% | |
Graham Classic formula value: 97.46
(P/E=8 * 1g) Min value: 63.65
(current P/E * 2g) Max value: 184.5
Average value: 115.2
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.